Thyroid cancer radiotheragnostics: the case for activity adjusted 131I therapy

@article{Avram2018ThyroidCR,
  title={Thyroid cancer radiotheragnostics: the case for activity adjusted 131I therapy},
  author={Anca M. Avram and Yuni K. Dewaraja},
  journal={Clinical and Translational Imaging},
  year={2018},
  volume={6},
  pages={335-346}
}
Radiotheragnostics represents the systematic integration of diagnostic imaging and therapeutics using radionuclides targeting specific characteristics of tumor biology. Radioiodine (131I) is the classic radiotheragnostic agent used for the diagnosis and treatment of differentiated thyroid cancer based on sodium-iodine symporter expression in normal and neoplastic thyroid tissue. Application of radiotheragnostics principles in thyroid cancer involves using pre-ablation diagnostic scans (Dx Scans… CONTINUE READING

Tables and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 90 REFERENCES

Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

  • The New England journal of medicine
  • 2012
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

  • The New England journal of medicine
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy

Michael Lassmann, Heribert Hänscheid, +3 authors Markus Luster
  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

a randomized study

HO Maenpaa, J Heikkonen, L Vaalavirta, M Tenhunen, cancer Joensuu H Low vs. high radioiodine activity to abl for
  • PLoS ONE 3(4):e1885 345 Clinical and Translational Imaging
  • 2018